Peptides for Weight Management

Peptides studied in metabolic contexts — including FDA-approved GLP-1/GIP receptor agonists and investigational compounds involved in appetite regulation and fat metabolism.

7 peptides coveredEducational reference only

Educational content only. The information on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making decisions about any medication or health intervention. Regulations and product availability vary by country and jurisdiction. Learn about peptide safety & regulation →

FDA Approved

Tirzepatide

Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound) studied for type 2 diabetes and chronic weight management, with extensive Phase 3 trial data.

FDA Approved

Semaglutide

Semaglutide is an FDA-approved GLP-1 receptor agonist (Ozempic, Wegovy) with robust clinical evidence for type 2 diabetes management and chronic weight loss.

Investigational

Retatrutide

LY3437943

Retatrutide is an investigational triple GLP-1/GIP/glucagon receptor agonist in Phase 3 TRIUMPH trials, demonstrating significant weight reduction in Phase 2 research.

Approved in China

Mazdutide

IBI362

Mazdutide is a dual GLP-1/glucagon receptor agonist approved in China for weight management and T2D; currently in Phase 2 US trials. Not FDA-approved.

Investigational

Survodutide

BI 456906

Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist in Phase 3 trials for obesity and MASH; not yet approved by any regulatory authority.

Investigational

Cagrilintide

CagriSema (combination)

Cagrilintide is a long-acting amylin analog studied in combination with semaglutide (CagriSema) in Phase 3 REDEFINE trials. It is not yet approved by any regulatory authority.

FDA Approved

Tesamorelin

Egrifta / Egrifta WR

Tesamorelin (Egrifta) is an FDA-approved GHRH analog indicated for HIV-associated lipodystrophy. It stimulates endogenous GH release and has Phase 3 trial data supporting its approved use.

Compare prices and lab grades

Use our price comparison and Finnrick lab data tools alongside this guide.